Free Trial

$1.5B Royalty Pharma 3Pt Launched; Guidance Updated Elsewhere

PIPELINE
  • Date $MM Issuer (Priced *, Launch #)
  • 6/3 $1.5B #Royalty Pharma $500M 5Y +100, $500M 10Y +127, $500M 30Y +152
  • 6/3 $Benchmark BNSF 30Y +98a
  • 6/3 $Benchmark Metlife 10Y +105a
  • 6/3 $Benchmark IDA 5Y SOFR+39a
  • 6/3 $Benchmark Nomura 5Y SOFR+39a
  • 6/3 $Benchmark NY Life 5Y +80a, 5Y SOFR
  • 6/3 $Benchmark Hyatt 5Y +125a, 10Y +150a
  • 6/3 $Benchmark GATX 10Y +130, 30Y +150
  • 6/3 $Benchmark Regions Financial 6NC5 +150a
  • 6/3 $800M Baltimore Gas WNG 10Y +93, 30Y +110
  • 6/3 $Benchmark Southwestern Public Service 30Y +150
  • 6/3 $Benchmark National Australia Bank (NAB) 3Y +70a, 3Y SOFR, 10Y +100a
  • 6/3 $Benchmark Brighthouse 2027 tap +115a, 5Y +140

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.